No profile data available.
Arbutus Biopharma Corporation (ABUS) is a healthcare company in the additional hormone and metabolic drugs industry, based in Warminster, United States, with about 19 full-time employees.
It reported revenue of $14.08 million for fiscal year 2025, up 128.2% from fiscal year 2024, and net income of -$33.50 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.01 million, down 90.6% from a year before. Its market capitalization was $646.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Arbutus Biopharma reported $14.08 million in revenue for fiscal year 2025, up 128.2% from $6.17 million in fiscal year 2024. In Q2 2026 revenue was $1.01 million.
$646.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Eton Pharmaceuticals, Inc. (ETON), MBX Biosciences, Inc. (MBX), Immix Biopharma, Inc. (IMMX), Rezolute, Inc. (RZLT).